AzurRx BioPharma's clinical trial hits midway point & more — 3 GI company key notes

Here are three updates on GI companies from the past week:

Boehringer Ingelheim Pharmaceuticals's Cyltezo, a second biosimilar for AbbVie's Humira, received FDA approval.

AzurRx BioPharma enrolled a sixth patient into its phase IIa trial for MS1819, a treatment for exocrine pancreatic insufficiency associated with chronic pancreatitis.

4D Pharma is preparing to move its irritable bowel syndrome drug, Blautix, into a phase II clinical trial.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast